NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

With both arms using Key after surgery

exwannabe,

In the control arm patients receive placebo before and after surgery.

Active Comparator: Group B (placebo, ATL-DC, poly ICLC)
Beginning 14 days prior to scheduled surgery, patients receive placebo IV. After surgery, patients receive placebo IV on day 1. Cycle repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive ATL-DC ID with poly ICLC IM every 2 weeks for up to 3 doses in the absence of disease progression or unacceptable toxicity.

https://clinicaltrials.gov/ct2/show/NCT04201873